At 18.0% CAGR, the Europe Stem Cell Therapy Market is projected to be worth US$ 1,209.01 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Europe stem cell therapy market was valued at US$ 446.75 million in 2022 and is expected to reach US$ 1,209.01 million by 2028, registering a CAGR of 18.0% from 2022 to 2028. Increasing research activities related to stem cell therapy for effective disease management and growing prevalence of cancer are the critical factors attributed to the Europe stem cell therapy market expansion.   

Stem cell therapy has been widely investigated across the world. Stem cells are mainly used to replace dying cells and reconstruct damaged tissues. Based on the results of extensive stem cell research conducted so far, many scientists have claimed that these cells could probably be utilized to generate cures and treatments for diseases such as cancer and cardiovascular disease. Newly developed stem cell therapies involve replacing disease-causing cells with stem cells. Many potential treatments involving stem cells are in different phases of clinical trials.

Researchers are further investigating the use of stem cell therapy in treating autoimmune disorders. For example, stem cells can turn into the cells of damaged organs and are used in treating autoimmune diseases. Treatment is carried out using mesenchymal stem cells or fetal stem cells. Hematopoietic stem cells are currently used for treating more than 80 medicals conditions, including immune system diseases, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and cancer types such as leukemia and lymphoma.

On the contrary, availability of illegal and unapproved products, and high cost of approved treatments hurdles the growth of Europe stem cell therapy market.

The Europe stem cell therapy market, by type, is segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and other stem cell therapy. The adult stem cell therapy segment held 60.0% market share in 2022, amassing US$ 268.03 million. It is projected to garner US$ 740.03 million by 2028 to expand at 18.4% CAGR during 2022–2028.  

Based on treatment, the Europe stem cell therapy market is bifurcated into allogeneic and autologous. The allogenic segment held 55.9% market share in 2022, amassing US$ 249.92 million. It is projected to garner US$ 667.03 million by 2028 to expand at 17.8% CAGR during 2022–2028.   

Based on application, the Europe stem cell therapy market is divided into musculoskeletal, dermatology, cardiology, drug discovery and development, other applications. The musculoskeletal segment held 33.2% market share in 2022, amassing US$ 148.14 million. It is projected to garner US$ 395.72 million by 2028 to expand at 17.8% CAGR during 2022–2028. 

The Europe stem cell therapy market, by end user, is segmented into academic & research institutes and hospitals & clinics. The academic & research institutes segment held 53.5% market share in 2022, amassing US$ 239.21 million. It is projected to garner US$ 656.14 million by 2028 to expand at 18.3% CAGR during 2022–2028.   

Based on country, the Europe stem cell therapy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 22.4% market share in 2022. It was assessed at US$ 100.27 million in 2022 and is likely to hit US$ 286.24 million by 2028, exhibiting a CAGR of 19.1% during the forecast period.

Key players dominating the Europe stem cell therapy market are MEDIPOST; BioTime, Inc.; Mesoblast Limited; TiGenix NV; Holostem Terapie Avanzate Srl; and NuVasive Inc, among others.

Few key developments in Europe stem cell therapy market:

• In 2022, MEDIPOST announced that the company has expanded the production facilities for its knee osteoarthritis stem cell products, CARTISTEM and SMUP-IA-01, and will start preparing for GMP (Good Manufacturing Practice) certification.
• In 2022, Mesoblast met with the FDA in December 2021 regarding its approval request. The company had generated “substantial new data” to show that immunomodulatory activity is a suitable measure to show the therapy's clinical effect in response.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com